Geron

Geron

Yahoo Finance • 2 days ago

Geron (GERN) Grants Inducement Stock Options to New Employees

Geron Corporation (NASDAQ:GERN) is one of the 10 Fastest Growing Tech Penny Stocks to Buy. On June 18, 2026, Geron Corporation (NASDAQ:GERN) reported that, effective June 17, 2026, it granted stock options to purchase an aggregate of 690,... Full story

Yahoo Finance • 2 days ago

Geron Announces Appointment of Chinmaya Rath as Chief Business Officer

FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Chinm... Full story

Yahoo Finance • 27 days ago

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective June 17, 2026, it granted stock options to purchase an aggregate of 690... Full story

Yahoo Finance • 2 months ago

Geron Q1 Earnings Call Highlights

Geron logo Key Points Q1 net revenue of $61.8 million (up 31% YoY) and Geron reiterated full‑year Rytelo guidance of $220–240 million, noting growth is weighted to H2 2026 while gross‑to‑net rose to 21% (expected low‑mid 20s for the year... Full story

Yahoo Finance • 3 months ago

Geron Corporation (GERN) Appoints Timothy Williams as EVP, Chief Legal Officer

Geron Corporation (NASDAQ:GERN) is one of the best growth stocks under $10 to invest in. On April 13, Geron Corporation appointed Timothy Williams as Executive Vice President, Chief Legal Officer, and Corporate Secretary. A seasoned legal... Full story

Yahoo Finance • 3 months ago

Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026

FOSTER CITY, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release it... Full story

Yahoo Finance • 5 months ago

Geron Corporation Q4 2025 Earnings Call Summary

Geron Corporation Q4 2025 Earnings Call Summary - Moby Strategic Alignment and Commercial Evolution Transitioned from a clinical-stage entity to a commercially minded organization through a strategic restructuring and leadership strength... Full story

Yahoo Finance • 5 months ago

Geron Q4 Earnings Call Highlights

Geron logo Key Points Geron reported strong commercial traction for RYTELO with Q4 net revenue of $48 million, full-year 2025 sales of $184 million, and 2026 guidance of $220–$240 million, driven by 9% quarter-over-quarter demand growth,... Full story

Yahoo Finance • 5 months ago

Geron falls as Q4 results miss expectations

[Close up image of wooden cubes with alphabet Q4 on office desk.] mohd izzuan Shares of Geron Corporation (GERN [https://seekingalpha.com/symbol/GERN]) lost ~15% in the premarket on Wednesday after the cancer drug developer missed Street... Full story

Yahoo Finance • 7 months ago

Geron strategic restructuring plan focuses on Rytelo growth

[Scissors separating employees on colorful blocks representing staff reduction] * Geron said that as part of its strategic restructuring plan, it will focus [https://seekingalpha.com/pr/20336521-geron-corporation-announces-strategic-res... Full story

Yahoo Finance • 7 months ago

Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS

Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemoglobin increases and transfusion independ... Full story

Yahoo Finance • 9 months ago

GERON (GERN) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Geron (GERN) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder of Geron securities between Februar... Full story

Yahoo Finance • 9 months ago

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders... Full story

Yahoo Finance • 9 months ago

Geron Corporation Announces Executive Leadership Transitions and Appointments

FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced several executive transi... Full story

Yahoo Finance • 11 months ago

SpyGlass Pharma Appoints Elizabeth O’Farrell to its Board of Directors

ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O’Farrell to its Board of Directors as an Independent Director... Full story

Yahoo Finance • 11 months ago

Geron Corporation Investors: Company Investigated by the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Geron Corporation (“Geron” or “the Company”) (NASDAQ: GERN) investors... Full story

Yahoo Finance • 11 months ago

Geron Corporation’s SWOT analysis: biotech stock faces growth hurdles amid positive outlook

Geron Corporation (NASDAQ:GERN), a biotechnology company focused on developing innovative therapies for hematologic malignancies, has been navigating a complex landscape of opportunities and challenges. The company’s flagship product, Ryte... Full story

Yahoo Finance • 11 months ago

GERON (GERN) ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Geron Corporation (NASDAQ: GERN) on behalf of long-term stockholders... Full story

Yahoo Finance • 11 months ago

Geron outlines 20% sales force expansion and expects RYTELO impact by year-end while advancing EU launch plans

Earnings Call Insights: Geron Corporation (GERN) Q2 2025 MANAGEMENT VIEW * Dawn Carter Bir, Interim President and CEO, highlighted the appointment of Harout Semerjian as Geron's new President and CEO, noting his commercial expertise in... Full story

Yahoo Finance • 11 months ago

Geron (GERN) Q2 Revenue Jumps 5,477%

Key Points GAAP revenue reached $49.0 million in Q2 2025, beating analyst estimates for both GAAP EPS and revenue. GAAP earnings per share improved to $(0.02). RYTELO demand rose 17% quarter-over-quarter following a challenging start to t... Full story